Diastolic dysfunction occurs early in HER2-positive breast cancer patients treated concurrently with radiation therapy and trastuzumab

Oncologist

Volumn 20, Issue 6, 2015, Pages 605-614

  Cao, Lu ^a,c   Cai, Gang ^a,c   Chang, Cai ^a,c   Miao, Ai Yu ^a,c   Yu, Xiao Li ^a,c   Yang, Zhao Zhi ^a,c   Ma, Jin Li ^a,c   Zhang, Qian ^a,c   Wu, Jiong ^a,c   Guo, Xiao Mao ^a,c   Chen, Jia Yi ^a,b,c  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

Breast cancer; Concurrent treatment; Diastolic dysfunction; Radiotherapy; Trastuzumab

Indexed keywords

ANTHRACYCLINE; CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; CARDIOTOXICITY; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; COMPARATIVE STUDY; DIASTOLIC DYSFUNCTION; DOPPLER FLOWMETRY; ECHOCARDIOGRAPHY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE OVEREXPRESSION; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PARTIAL MASTECTOMY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TISSUE DOPPLER IMAGING; BREAST NEOPLASMS; CARDIOMYOPATHY; CHEMICALLY INDUCED; COMPLICATION; DIAGNOSTIC IMAGING; DIASTOLIC HEART FAILURE; DRUG EFFECTS; GENETICS; HEART LEFT VENTRICLE FUNCTION; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; RADIOGRAPHY;

ADULT; AGED; BREAST NEOPLASMS; CARDIOMYOPATHIES; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE, DIASTOLIC; HUMANS; MIDDLE AGED; RADIOGRAPHY; RECEPTOR, ERBB-2; TRASTUZUMAB; VENTRICULAR FUNCTION, LEFT;

EID: 84932616186     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0299     Document Type: Article

References (43)

1. Clarke M, Collins R, Darby S et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;366:2087–2106.
2. Darby SC, McGale P, Taylor CW et al. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: Prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol 2005;6:557–565.
3. Marks LB, Yu X, Prosnitz RG et al. The incidence and functional consequences of RT-associated cardiac perfusion defects. Int J Radiat Oncol Biol Phys 2005;63:214–223.
4. Giordano SH, Kuo YF, Freeman JL et al. Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst 2005;97:419–424.
5. Patt DA, Goodwin JS, Kuo YF et al. Cardiac morbidity of adjuvant radiotherapy for breast cancer. J Clin Oncol 2005;23:7475–7482.
6. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breastcancer. N Engl J Med 2005;353: 1659–1672.
7. Yin W, Jiang Y, Shen Z et al. Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: A meta-analysis of published randomized controlled trials. PLoS One 2011;6: e21030.
8. Pietras RJ, Poen JC, Gallardo D et al. Monoclonal antibodytoHER-2/neureceptormodulatesrepairof radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells over-expressing this oncogene. Cancer Res 1999;59: 1347–1355.
9. Liang K, Lu Y, Jin W et al. Sensitization of breast cancercellstoradiationbytrastuzumab. MolCancer Ther 2003;2:1113–1120.
10. Sherief LM, Kamal AG, Khalek EA et al. Biomarkers and early detection of late onset anthracycline-induced cardiotoxicity in children. Hematology 2012;17:151–156.
11. Mukherjee M, Dusaj R, Stewart K et al. Predictors of abnormal longitudinal strain using left ventricular speckle tracking in ambulatory hypertensive patients with preserved ejection fraction. J Am Coll Cardiol 2013.
12. Redfield MM, Jacobsen SJ, Burnett JC Jr. et al. Burden of systolic and diastolic ventricular dysfunction in the community: Appreciating the scope of the heart failure epidemic. JAMA 2003;289:194–202.
13. Zaya M, Mehta P, Mohammadi AH et al. Microvascular coronary dysfunction, left ventricular volumes and mass: Results from the women’sischemia syndrome evaluation-coronary vascular dysfunction study. J Am Coll Cardiol 2013;61:E1442.
14. Gagliardi G, Constine LS, Moiseenko V et al. Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys 2010;76(suppl):S77–S85.
15. Cao L, Hu W G, Kirova YM et al. Potentialimpact of cardiac dose-volume on acute cardiac toxicity following concurrent trastuzumab and radiotherapy. Cancer Radiother 2014;18:119–124.
16. Edge SB, Compton CC. The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010;17:1471–1474.
17. Kestin LL, Sharpe MB, Frazier RC et al. In-tensitymodulationtoimprovedose uniformitywith tangential breast radiotherapy: Initial clinical experience. Int J Radiat Oncol Biol Phys 2000;48: 1559–1568.
18. Hui G, Jianrong D, Yexiong L et al. A simplified intensitymodulated radiationtherapytechniquefor difficult clinical cancer condition. Chinese Journal of Radiation Oncology 2006;15:411–415.
19. Radiation Therapy Oncology Group. Breast cancer contouring atlas. Available at http://www.rtog.org/CoreLab/ContouringAtlases/BreastCancerAtlas.aspx.
20. Feng M, Moran JM, Koelling T et al. Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. Int J Radiat Oncol Biol Phys 2011; 79:10–18.
21. 21. Taylor CW, Nisbet A, McGale P et al. Cardiac exposures in breast cancer radiotherapy: 1950s– 1990s. Int J Radiat Oncol Biol Phys 2007;69:1484–1495.
22. Erven K, Florian A, Slagmolen P et al. Subclinical cardiotoxicity detected by strain rate imaging up to 14 months afterbreast radiation therapy. IntJRadiat Oncol Biol Phys 2013;85:1172–1178.
23. Simonson JS, Schiller NB. Descent of the base of the left ventricle: An echocardiographic index of left ventricular function. J Am Soc Echocardiogr 1989;2:25–35.
24. Paulus WJ, Tschöpe C, Sanderson JE et al. How to diagnose diastolic heart failure: A consensus statement on the diagnosis of heart failure with normal left ventricular ejection fractionbythe Heart Failure and Echocardiography Associations of the EuropeanSocietyofCardiology. Eur Heart J 2007;28: 2539–2550.
25. Heidenreich PA, Hancock SL, Vagelos RH et al. Diastolic dysfunction after mediastinal irradiation. Am Heart J 2005;150:977-982.
26. Hardenbergh PH, Munley MT, Bentel GC et al. Cardiac perfusion changes in patients treated for breast cancer with radiation therapy and doxorubicin: Preliminary results. Int J Radiat Oncol Biol Phys 2001;49:1023-1028.
27. Adams MJ, Hardenbergh PH, Constine LS et al. Radiation-associated cardiovascular disease. Crit Rev Oncol Hematol 2003;45:55-75.
28. 28. Yavas G, Yildiz F, Guler S et al. Concomitant trastuzumab with thoracic radiotherapy: A morphological and functional study. Ann Oncol 2011;22: 1120-1126.
29. Cochet A, Quilichini G, Dygai-Cochet I et al. Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer. Breast Cancer Res Treat 2011;130:845-854.
30. Crone SA, Zhao YY, Fan Letal.ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002;8:459-465.
31. Halyard MY, Pisansky TM, Dueck AC et al. Radiotherapyand adjuvanttrastuzumab in operable breast cancer: Tolerability and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol 2009;27:2638-2644.
32. Shaffer R, Tyldesley S, Rolles M et al. Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal mammary chain nodes: A retrospectivesingle-institution study. Radio-ther Oncol 2009;90:122-126.
33. Belkacemi Y, Gligorov J, Ozsahin M et al. Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: Acute toxicityanalyses from the French multicentric study. Ann Oncol 2008;19:1110-1116.
34. Nishimura RA, Tajik AJ. Evaluation of diastolic filling of left ventricle in health and disease: Doppler echocardiography is the clinician’s Rosetta Stone. J Am Coll Cardiol 1997;30:8-18.
35. Stewart JR, Fajardo LF. Radiation-induced heart disease. Clinical and experimental aspects. Radiol Clin North Am 1971;9:511-531.
36. Beckham WA, Popescu CC, Patenaude VV et al. Is multibeam IMRT better than standard treatment for patients with left-sided breast cancer? Int J Radiat Oncol Biol Phys 2007;69:918-924.
37. Coon AB, Dickler A, Kirk M C et al.Tomotherapy and multifield intensity-modulated radiotherapy planning reduce cardiac doses in left-sided breast cancer patients with unfavorable cardiac anatomy. Int J Radiat Oncol Biol Phys 2010;78:104-110.
38. 38. Tarantini L, Gori S, Faggiano P et al. Adjuvant trastuzumab cardiotoxicity in patients over 60years of age with early breast cancer: A multicenter cohort analysis. Ann Oncol 2012;23:3058-3063.
39. Grodecki PV, Klein AL. Pitfalls in the echo-Doppler assessment of diastolic dysfunction. Echocardiography 1993;10:213-234.
40. Bella JN, Palmieri V, Roman MJ et al. Mitral ratio of peak early to late diastolic filling velocity as a predictor of mortality in middle-aged and elderly adults: The Strong Heart Study. Circulation 2002; 105:1928-1933.
41. 41. Tschope C, Kasner M, Westermann D et al.The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: Correlation with echocardiographic and invasive measurements. Eur Heart J 2005;26:2277-2284.
42. Kilickap S, Barista I, Akgul E et al. cTnT can be a useful marker for early detection of anthracycline cardiotoxicity. Ann Oncol 2005;16:798-804.
43. Nagueh SF, Appleton CP, Gillebert TC et al. Recommendations for the evaluation of left ven-triculardiastolic function by echocardiography. EurJ Echocardiogr 2009;10:165-193.